新股评级 | 瑞科生物-B：冲击 “港股 HPV 疫苗第一股”

Gelonghui
2022.03.21 00:59

引入 3 名基石投资者

今天为大家带来【瑞科生物-B】的新股评级。本评级主要围绕基本盘、实操盘两大维度，针对目标公司各项核心指标进行打分评级，满分为 10 分，各指标单独评分，按 “(权重占比 * 分数) 之和” 计算，最终结果按照四舍五入得到。格隆汇新股研究根据已公开数据及独家的内部评级体系，给予【瑞科生物-B】的新股综合评估分数为【8.2】(满分为 10 分），如下图：

Source: Gelonghui The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.